Clinical Policy: Octreotide Acetate (Sandostatin, Sandostatin LAR Depot)
Reference Number: CP.PHAR.40
Effective Date: 03.01.10
Last Review Date: 02.19
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Octreotide acetate (Sandostatin® Injection, Sandostatin® LAR Depot) is a somatostatin analogue.

FDA Approved Indication(s)
Sandostatin Injection (SC/IV) is indicated:
- Acromegaly
  - To reduce blood levels of growth hormone (GH) and insulin-like growth factor (IGF-I (somatomedin C) in acromegaly patients who have had inadequate response or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses;
- Carcinoid tumors*
  - For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease
- Vasoactive intestinal peptide tumors* (VIPomas)
  - For the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors

Sandostatin LAR Depot (IM) is indicated for treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for:
- Acromegaly
- Carcinoid tumors*
  - Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors
- Vasoactive intestinal peptide tumors* (VIPomas)
  - Profuse watery diarrhea associated with VIP-secreting tumors

*Neuroendocrine tumors

Limitation(s) of use:
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases, has not been determined.

Policy/Criteria
Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.
It is the policy of health plans affiliated with Centene Corporation® that Sandostatin Injection and Sandostatin LAR Depot are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Acromegaly (must meet all):
      1. Diagnosis of acromegaly;
      2. Age ≥ 18 years or, if younger, epiphyseal growth plates have closed;
      3. Inadequate response to surgical resection or pituitary irradiation (i.e., unable to achieve normalization of GH and/or IGF-I levels or unable to adequately control tumor mass), or member is not a candidate for such treatment;
      4. Request is for either of the following formulations (both products may be used together) (a or b):
         a. Sandostatin Injection: Dose does not exceed 1,500 mcg per day in divided doses;
         b. Sandostatin LAR Depot (i and ii):
            i. Dose does not exceed 40 mg every 4 weeks.
            ii. Member has received Sandostatin Injection for at least two weeks with improvement in GH or IGF-I levels, or tumor mass control.
   Approval duration:
   Medicaid/HIM - 6 months
   Commercial – 6 months or to the member’s benefit renewal date, whichever is longer
   
   B. Carcinoid Tumor - Neuroendocrine Tumor of the Gastrointestinal Tract, Lung and Thymus (must meet all):
      1. Diagnosis of a carcinoid tumor (most commonly arising in the lungs and bronchi, small intestine, appendix, rectum, or thymus) and one of the following (a or b):
         a. Request is for carcinoid syndrome (i.e., presence of diarrhea or flushing symptoms indicative of hormonal hypersecretion);
         b. Request is for advanced disease, with or without carcinoid syndrome;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. Request is for any of the following (both products may be used together) (a, b, or c):
         a. Sandostatin Injection: Dose does not exceed 1500 mcg per day in divided doses;
         b. Sandostatin LAR Depot (i and ii):
            i. Dose does not to exceed 30 mg every 4 weeks;
            ii. If request is for symptom management only, member has received Sandostatin Injection for at least two weeks with improvement in diarrhea or flushing episodes;
            c. Dose for Sandostatin Injection or Sandostatin LAR Depot is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   Approval duration:
   Medicaid/HIM - 6 months
   Commercial – 6 months or to the member’s benefit renewal date, whichever is longer
C. Vasoactive Intestinal Peptide Tumor and other Pancreatic Neuroendocrine Tumors (must meet all):
1. Diagnosis of a pancreatic neuroendocrine tumor including but not limited to VIPoma, gastrinoma, insulinoma or glucagonoma, and one of the following (a, b, c, or d):
   a. Request is for management of symptoms indicative of hormonal hypersecretion (e.g., diarrhea);
   b. Request is for treatment of a gastrinoma with or without symptoms;
   c. For other pancreatic neuroendocrine tumors, request is for advanced disease, with or without symptoms;
   d. If request is for an insulinoma, tumor is somatostatin receptor positive on imaging;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Request is for any of the following (both products may be used together) (a, b, or c):
   a. Sandostatin injection:
      i. Dose does not exceed 750 mcg per day in divided doses;
   b. Sandostatin LAR Depot (i and ii):
      i. Dose does not exceed 30 mg every 4 weeks;
      ii. If request is for symptom management only, member has received Sandostatin Injection for at least two weeks with improvement in symptoms prior to request for Sandostatin LAR Depot.
   c. Dose for Sandostatin Injection or Sandostatin LAR Depot is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM - 6 months
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

D. Meningioma (off-label) (must meet all):
1. Diagnosis of meningioma (cancer of the central nervous system);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Disease is not amenable to surgery or radiation;
5. Octreotide scan is positive;
6. Dose for Sandostatin Injection and/or Sandostatin LAR Depot is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM - 6 months
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

E. Thymoma and Thymic Carcinoma (off-label) (must meet all):
1. Diagnosis of thymoma or thymic carcinoma;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Second-line therapy (first-line therapies include CAP [cisplatin, doxorubicin, cyclophosphamide], ADOC [cisplatin, doxorubicin, vincristine, cyclophosphamide], PE [cisplatin, etoposide], VIP [etoposide, ifosfamide, cisplatin], carboplatin/paclitaxel);
5. Dose for Sandostatin Injection and/or Sandostatin LAR Depot is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM - 6 months
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

F. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Acromegaly (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
   2. Member is responding positively to therapy (e.g., improvement in GH or IGF-1 serum concentrations, or in tumor mass control, since initiation of therapy);
   3. If request is for a dose increase, request is for either of the following (both products may be used together) (a or b):
      a. Sandostatin Injection: New dose does not exceed 1,500 mcg per day in divided doses;
      b. Sandostatin LAR Depot: New dose does not exceed 40 mg every 4 weeks.

Approval duration:
Medicaid/HIM - 6 months
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

B. Carcinoid Tumor - Neuroendocrine Tumor of the Gastrointestinal Tract, Lung and Thymus (must meet all):
   1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Sandostatin or Sandostatin LAR for carcinoid tumor and has received this medication for at least 30 days;
   2. Member is responding positively to therapy;
   5. If request is for a dose increase, request is for any of the following (both products may be used together) (a, b, or c):
      a. Sandostatin Injection: New dose does not exceed 1500 mcg per day in divided doses;
      b. Sandostatin LAR Depot: New dose does not exceed 30 mg every 4 weeks.
C. Vasoactive Intestinal Peptide Tumor and other Pancreatic Neuroendocrine Tumors (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Sandostatin and/or Sandostatin LAR for a VIPoma and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request is for any of the following (both products may be used together) (a, b, or c):
   a. Sandostatin injection: New dose does not exceed 750 mcg/day in divided doses;
   b. Sandostatin LAR Depot: New dose does not exceed 30 mg every 4 weeks;
   c. New dose for Sandostatin Injection or Sandostatin LAR Depot is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM - 6 months
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

D. Meningioma (off-label) (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose for Sandostatin Injection and/or Sandostatin LAR Depot is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM - 6 months
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

E. Thymoma and Thymic Carcinoma (off-label) (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose for Sandostatin Injection and/or Sandostatin LAR Depot is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM - 6 months  
Commercial – 6 months or to the member’s benefit renewal date, whichever is longer

F. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   GH: growth hormone  
   IGF-1: insulin growth factor 1 (somatomedin C)  
   VIPoma: vasoactive intestinal peptide tumor

   Appendix B: Therapeutic Alternatives
   Not applicable

   Appendix C: Contraindications/Boxed Warnings
   Sandostatin LAR Depot: None reported  
   Sandostatin Injection:
      • Contraindication(s): Sensitivity to this drug or any of its components.
      • Boxed warning(s): None reported.

   Appendix D: General Information
   Acromegaly: GH excess occurring in growing children/adolescents before epiphyseal growth plate closure (known as pituitary gigantism) is not included in the present policy given unique etiologic and management considerations.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide acetate (Sandostatin Injection) (SC or IV)</td>
<td>Acromegaly</td>
<td>Up to 1500 mcg in 2 or more divided doses</td>
<td>1500 mcg/day</td>
</tr>
<tr>
<td></td>
<td>Carcinoid tumors</td>
<td>Up to 1500 mcg in 2 or more divided doses</td>
<td>1500 mcg/day</td>
</tr>
</tbody>
</table>
### Drug Name

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide acetate (Sandostatin LAR Depot) (IM)</td>
<td>VIPomas</td>
<td>Up to 750 mcg in 2 or more divided doses</td>
<td>750 mcg/day</td>
</tr>
<tr>
<td></td>
<td>Acromegaly</td>
<td>20-40 mg every 4 weeks</td>
<td>40 mg/4 weeks</td>
</tr>
<tr>
<td></td>
<td>Carcinoid tumors</td>
<td>20-30 mg every 4 weeks</td>
<td>30 mg/4 weeks</td>
</tr>
<tr>
<td></td>
<td>VIPomas</td>
<td>20-30 mg every 4 weeks</td>
<td>30 mg/4 weeks</td>
</tr>
</tbody>
</table>

### VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide acetate (Sandostatin Injection)</td>
<td>Single-use ampule: 50 mcg/mL, 100 mcg/mL, 500 mcg/mL Multi-dose vial: 200 mcg/mL, 1000 mcg/mL</td>
</tr>
<tr>
<td>Octreotide acetate (Sandostatin LAR Depot)</td>
<td>Single-use kit (vial): 10 mg, 20 mg, 30 mg</td>
</tr>
</tbody>
</table>

### VII. References


### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
### HCPCS Codes

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2353</td>
<td>Injection, octreotide, depot form for intramuscular injection, 1 mg</td>
</tr>
<tr>
<td>J2354</td>
<td>Injection, octreotide, nondepot form for subcutaneous or intravenous injection, 25 mcg</td>
</tr>
</tbody>
</table>

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Added limitations of use to Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Removed prospective question regarding stopping therapy to Figure 1</td>
<td>05.01.14</td>
<td>06.14</td>
</tr>
<tr>
<td>Updated background to include Carcinoid tumors and VIPoma and safety warnings. Updated Appendix E and references.</td>
<td>02.01.15</td>
<td>05.15</td>
</tr>
<tr>
<td>For all three indications: Age added per PI; documentation requests removed; dosing parameters added per PI; initial approval period increased to 3 months. Acromegaly: Bromocriptine requirement removed; cabergoline; monitoring parameters edited to include IGF-1, GH and tumor mass; removed requirement that member have clinical evidence of acromegaly per App B. Carcinoid tumors: Clarified that carcinoid tumors are now known as neuroendocrine tumors of the GI tract, lung, and thymus; removed requirement that member be experiencing carcinoid syndrome as outlined in App D; removed question about whether member is a candidate for surgery as surgery can be used with octreotide to cure or control. VIPomas: Removed the requirement that patients try other medications for diarrhea; as with carcinoid tumors, questions about surgery are removed. The following criteria in section A “acromegaly” is removed: “If member has received pituitary irradiation Sandostatin LAR Depot will be withdrawn yearly for approximately 8 weeks to assess disease activity (if GH or IGF-1 levels increase and signs and symptoms recur Sandostatin LAR Depot therapy may be resumed).” Hypersensitivity removed as a contraindication. Acromegaly continuation criteria edited to allow 12 months of therapy before evidence of efficacy; renewal approval durations throughout policy are lengthened to 12 months. NCCN compendial uses are added for carcinoids and VIPomas in section D.</td>
<td>03.01.16</td>
<td>05.16</td>
</tr>
<tr>
<td>1Q18 annual review: - Policies combined for Medicaid and Commercial lines of business -Specialist added for oncology indications</td>
<td>11.30.17</td>
<td>02.18</td>
</tr>
</tbody>
</table>
**Clinical Policy**  
Octreotide Acetate

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
</table>
| - Requests for non-oncology off-label indications and any oncology off-label indications not outlined above are directed to the off-label use policies referenced in Section I.F.  
- Positive therapeutic response examples (diarrhea, flushing, disease progression, unacceptable toxicity) are removed as they are not amenable to objective measurement.  
- References updated. Updated approval duration to 6 months.                                   |        |                  |
| 1Q 2019 annual review; HIM line of business added; off-label NCCN recommended uses added for tumor control of neuroendocrine tumors with or without symptoms; positive octreotide scan added for insulinoma and meningioma per NCCN; references reviewed and updated. | 11.13.18 | 02.19            |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
CLINICAL POLICY
Octreotide Acetate

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2010 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.